Anti-Human HLA-DRB1 Reference Antibody (Apolizumab, RUO) (HF974016)

Name: Anti-Human HLA-DRB1 Reference Antibody (Apolizumab, RUO)
Brand: abinScience
SKU: HF974016
Price: 176 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HF974016
Description	Apolizumab (HF974016) is a research-grade recombinant antibody targeting HLA class II histocompatibility antigen. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG1-nd
Système d'expression	Mammalian cells
Cible	HLA class II histocompatibility antigen, DRB1 beta chain, Human leukocyte antigen DRB1, HLA-DRB1
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P01911
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	Hu1D10, 267227-08-7
Contexte	HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1) is a ~29 kDa protein. A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells. Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes. In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins. 1. Shams, H. et al. (2004) Journal of immunology (Baltimore, Md. : 1950) 173, 1966-77. PMID: 15265931 2. Schulze zur Wiesch, J. et al. (2005) Journal of immunology (Baltimore, Md. : 1950) 175, 3603-13. PMID: 16148104 3. Kwok, WW. et al. (2012) Journal of immunology (Baltimore, Md. : 1950) 188, 2537-44. PMID: 22327072 4. Muehling, LM. et al. (2016) Journal of immunology (Baltimore, Md. : 1950) 197, 3214-3224. PMID: 27591323 5. Galperin, M. et al. (2018) Science immunology 3. PMID: 29884618 6. Abelin, JG. et al. (2019) Immunity 51, 766-779.e17. PMID: 31495665 7. Topalian, SL. et al. (1996) The Journal of experimental medicine 183, 1965-71. PMID: 8642306 8. Stern, LJ. et al. (1994) Nature 368, 215-21. PMID: 8145819 9. Schmid, D. et al. (2007) Immunity 26, 79-92. PMID: 17182262
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 (LALAPG) Recombinant Isotype Control Antibody (HyHEL-10) (HP688307) Human IgG1 (LALA) Recombinant Isotype Control Antibody (HyHEL-10) (HP688107)